UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPF	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Cohen Yuval			2. Issuer Name and Ticker or Trading Symbol						D1	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O CORBUS PHARMACEUTICALS		3. Date of Earliest Transaction (Month/Day/Year) 02/02/2021												
(Street)								_X_						
	(State)	(Zip)			т	'abla i	I Non Donis	vativa Caanniti						
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea		ar) any		ed 3 Date, if (3. Tran Code Instr.	nsaction 4. (A	A) or Disposed of (D) Instr. 3, 4 and 5)		5. Amount of Securities Be Owned Following Reporte Transaction(s) (Instr. 3 and 4)		neficially (Direct (D) or Indirect I)	Beneficial Ownership	
Report on a s	separate line for eacl		- Deriva	tive	Securitie	s Acq	Persons in this for a curren	orm are not rently valid OME	equired to B control r eficially Ow	respond u number.				474 (9-02)
	n Date (Month/Day/Year) Execution any (Month	any	4. Transaction Code		5. Number of Derivative Securities Acquired (A)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			Derivative Securities Beneficially Owned Following Reported	Ownershi Form of Derivative Security: Direct (D) or Indirec	Beneficia Ownersh (Instr. 4)
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
\$ 2.58	02/02/2021		A		956,500)	(1)	02/02/2031	Commor Stock	956,500	\$ 0	956,500	D	
\$ 2.58	02/02/2021		A		956,500)	(2)	02/02/2031	Commor Stock	956,500	\$ 0	956,500	D	
	Zuval ast) RBUS PHA NGS, INC, DOD, MA ity) Report on a service of Derivative Security \$ 2.58	RBUS PHARMACEUTICANGS, INC, 500 RIVER RIE (Street) DOD, MA 02062 (State) Report on a separate line for each or Exercise Price of Derivative Security \$ 2.58 02/02/2021	RBUS PHARMACEUTICALS NGS, INC, 500 RIVER RIDGE DRIVE (Street) DOD, MA 02062 (Street) Security Report on a separate line for each class of securities by the conversion of Exercise Price of Derivative Security \$ 2.58 02/02/2021	Table II - Derivative Security Table II - Date (Month/Day/Year) 2. Table II - Derivative Security Table II - Date (Month/Day/Year) 2. Transaction Date (A.S., price of Derivative Security 2. Transaction Date (Month/Day/Year) 2. Table II - Derivative (A.S., price of Derivative Security Security Table II - Derivative (A.S., price of Derivative Security) A A Code \$ 2.58 02/02/2021 A	Table II - Derivative (e.g., puts, Price of Derivative Security 2.	Corbus Pharmacer RBUS PHARMACEUTICALS NGS, INC, 500 RIVER RIDGE DRIVE (Street) OOD, MA 02062 Security Corbus Pharmacer 3. Date of Earliest Tra 02/02/2021 4. If Amendment, Date Execution Date (Month/Day/Year) And Demed Execution Date, if any (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Table II - Derivative Securitie (e.g., puts, calls, war (Month/Day/Year) And Derivative Securitie (e.g., puts, calls, war (Month/Day/Year) Acquired or Dispos (D) (Instr. 3, and 5) Code V (A) \$ 2.58 02/02/2021 A 956,500	Corbus Pharmaceutical (Middle) (Middle) (Street) (Street) (Street) (Street) (Street) (Street) (A. If Amendment, Date Original (Month/Day/Year) (State) (Zip) (A. If Amendment, Date Original (Month/Day/Year) (Month/Day/Year) (A. If Amendment, Date Original (A. If Amendment, Date Original (Month/Day/Year) (A. If Amendment, Date Original (Month/Day/Year) (A. If Amendment, Date Original (A. If Amendment, Date Original (Month/Day/Year) (A. If Amendment, Date Original (Month/Day/Y	Corbus Pharmaceuticals Holdings (Site Pharmaceuticals Holdings) (An If Amendment, Date Original Filed(Month/Day/Year) (And Code (An Instruction Date, if Code (An Instruction Date) (An Instruction Date) (And Code (An Instruction Date) (An Inst	Corbus Pharmaceuticals Holdings, Inc. [CRB strikes] (Middle) (Pists) (Middle) (Strikes) (Strikes) (Strikes) (Strikes) (Strikes) (Strikes) (Strikes) (Zip) (State) (Zip) (State) (Zip) (Anoth/Day/Year) (Anoth/Day/	Corbus Pharmaceuticals Holdings, Inc. [CRBP] (Street) (A) or Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 3) (A) or Disposed of (D) (Instr. 3) (A) or Disposed of or Beneficially Ower directly or indirectly. (Code V Amount (D) Price of Derivative Securities (Month/Day/Year) (Month/Day/Year)	Corbus Pharmaceuticals Holdings, Inc. [CRBP] as) (First) (Middle) (Street)	Corbus Pharmaceuticals Holdings, Inc. [CRBP] (Check Surface) (Street) (A) or Disposed of (D) (Onwed Following Reported Transaction (Instr. 3 and 4) (Instr. 3 and 4) (Instr. 3 and 4) (Ronth/Day/Year) (Instr. 3) (Instr.	Corbus Pharmaceuticals Holdings, Inc. [CRBP] (First) (Middle) (Signer) (Signer) (Signer) (Signer) (S	Corbus Pharmaceuticals Holdings, Inc. [CRBP] (Check all applicable) (Check a

		Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Cohen Yuval C/O CORBUS PHARMACEUTICALS HOLDINGS, IN 500 RIVER RIDGE DRIVE NORWOOD, MA 02062	IC X		Chief Executive Officer				

Signatures

/s/ Sean Moran, attorney-in-fact for Yuval Cohen	02/04/2021	
**Signature of Reporting Person	Date	

Explanation of Responses:

 \star If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022.
- (2) Represents a special retention award comprised of options to purchase common stock. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.